Oramed Pharmaceuticals Inc. (TLV:ORMP)

Oramed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	1.34	2.7	2.71	2.71
Revenue Growth (YoY)	-	-50.42%	-0.33%	-	0.33%
Gross Profit	-	1.34	2.7	2.71	2.71
Selling, General & Admin	6.46	8.14	15.66	12.58	4.73
Research & Development	6.32	8.97	27.64	27.11	20.67
Operating Expenses	12.78	17.11	43.3	39.69	25.4
Operating Income	-12.78	-15.77	-40.6	-36.98	-22.68
Interest Expense	-0.85	-2.04	-	-	-0.07
Interest & Investment Income	-	8.03	3.57	0.47	0.78
Currency Exchange Gain (Loss)	-	-0.12	0.18	-0.03	-
Other Non Operating Income (Expenses)	-2.29	-1.4	-0.01	-0.01	-
EBT Excluding Unusual Items	-15.92	-11.3	-36.86	-36.55	-21.97
Gain (Loss) on Sale of Investments	-	16.39	-0.81	-0.22	-
Pretax Income	-15.92	5.09	-37.66	-36.77	-21.97
Income Tax Expense	3.18	-	0.1	-	-
Earnings From Continuing Operations	-19.1	5.09	-37.76	-36.77	-21.97
Minority Interest in Earnings	0.04	0.44	1.2	1.76	-
Net Income	-19.06	5.53	-36.56	-35	-21.97
Net Income to Common	-19.06	5.53	-36.56	-35	-21.97
Shares Outstanding (Basic)	41	40	39	37	24
Shares Outstanding (Diluted)	41	41	39	37	24
Shares Change (YoY)	0.65%	4.02%	5.08%	52.14%	39.76%
EPS (Basic)	-0.47	0.14	-0.94	-0.94	-0.90
EPS (Diluted)	-0.48	0.14	-0.94	-0.94	-0.90
Free Cash Flow	-8.43	-10.55	-28.41	-33.39	-25.75
Free Cash Flow Per Share	-0.21	-0.26	-0.73	-0.90	-1.06
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-1176.79%	-1501.96%	-1363.50%	-836.39%
Profit Margin	-	412.31%	-1352.61%	-1290.71%	-810.18%
Free Cash Flow Margin	-	-787.24%	-1051.20%	-1231.31%	-949.45%
EBITDA	-12.59	-15.57	-40.54	-36.92	-22.66
D&A For EBITDA	0.19	0.2	0.06	0.05	0.02
EBIT	-12.78	-15.77	-40.6	-36.98	-22.68

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.